If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,376.00
Bid: 12,374.00
Ask: 12,378.00
Change: 44.00 (0.36%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Dollar hits two-year lows as traders ignore U.S. stimulus delays

Wed, 30th Dec 2020 08:57

* Dollar falls to lowest since April 2018

* Pound boosted by UK Oxford/AstraZeneca vaccine approval

* Aussie, Kiwi gain versus dollar

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

LONDON, Dec 30 (Reuters) - The dollar sunk to its lowest in
more than two years in Asian trading on Wednesday and riskier
currencies surged, as investors looked past the latest delay in
U.S. fiscal stimulus and bet that global market risk appetite
would increase in 2021.

U.S. Senate Majority Leader Mitch McConnell on Tuesday
blocked a vote on increasing COVID-19 relief payments to $2,000,
adding another delay to fractious negotiations over fiscal
stimulus.

But market sentiment was upbeat as investors remained
optimistic that a fiscal stimulus deal will be eventually
reached, lessening demand for the safe-haven dollar.

The latest setback "doesn’t really matter too much for
investors as they have been over the moon on the back of news
that there is still plenty of fiscal support for the U.S.
economy," Naeem Aslam, chief market analyst at Avatrade, said in
a note.

Analysts expect the dollar to weaken further in 2021 as U.S.
President-elect Joe Biden is expected to push for even more
measures to support the U.S. economy.

The "risk-on" moves in currency markets peaked in the Asian
session on Wednesday, then eased off as European markets opened.

At 0816 GMT, the dollar was down around 0.1% versus a basket
of currencies, at 89.895, having dropped as low as 89.711
overnight. The euro was up at $1.226.

The Australian dollar - seen as a liquid proxy for global
risk appetite - was up 0.6% on the day at 0.76475 at 0825 GMT
. The New Zealand dollar also hit two-year highs
.

The dollar lost out to the Japanese yen, with dollar-yen
down 0.2% at 103.34 at 0834 GMT.

In Europe, sentiment was buoyed by Britain becoming the
first country in the world to approve the COVID-19 vaccine
developed by AstraZeneca and Oxford University.

The British pound was up against the dollar, at $1.3538, but
little changed against the euro, as traders returning from the
Christmas break digested the Brexit deal struck on Dec. 24.

Although the agreement avoids a chaotic no-deal exit, it
does not cover services, which make up 80% of the British
economy.

Commonwealth Bank of Australia senior currency strategist
Elias Haddad wrote in a note to clients that the fact that the
deal does not provide an equivalence framework for financial
service and growing support for Scottish independence are new
headwinds for the pound.

Euro zone government bond yields edged up by around one
basis point, with Germany's benchmark 10-year yield at -0.56% at
0827 GMT.

Elsewhere, Bitcoin reached a record high of $28,599.99,
taking its yearly gain for the world's most popular
cryptocurrency past 295%.

(Reporting by Elizabeth Howcroft, editing by Larry King)

More News
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.